- Poster presentation
- Open Access
Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar
© Teppler et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Integrase Inhibitor
- Identical Phase
- P004 Result
Raltegravir (RAL) is the first approved HIV integrase inhibitor and has demonstrated potent efficacy in both treatment-experienced and -naïve HIV-infected patients (pts). This analysis reports long-term efficacy data from one Phase II and two Phase III studies in pts infected with non-B subtype virus.
In total, 622 pts were randomized to RAL and 275 to comparator across the three studies. Non-B subtype virus was isolated at baseline in 62 pts in the RAL groups (23 from P004), and in 23 pts in the comparator groups (8 from P004). Subtypes AE and D were most common, isolated in 40 and eight pts, respectively. Data are available for 58/62 and 22/23 of pts with non-B subtype virus using the observed failure approach for % with RNA < 50 copies/mL (see table in Figure 1). RAL-treated pts demonstrated increases from baseline in CD4 of 216 and 250 cells/mm3 for B and non-B, respectively, at week 96 in P004, and of 105 and 150 cells/mm3, for B and non-B, respectively, at week 48 in BENCHMRK-1 and -2.
In these studies, RAL showed similar and potent clinical efficacy in patients with B subtype and non-B subtype HIV in both treatment-naïve and treatment-experienced populations.
This article is published under license to BioMed Central Ltd.